WARPTECHNEWS · LAB

Home AI Business Tech Archive

WARPTECH NEWS· by Warptech Lab

© 2026120+ international sourcesupdated hourly

Storia: FDA Approves Eli Lilly’s GLP-1 Pill — Warptech News

Storia in 5 fonti

FDA Approves Eli Lilly’s GLP-1 Pill

Eli Lilly’s once-daily Foundayo is the second obesity pill to receive FDA approval. It will compete with Novo Nordisk’s pill version of Wegovy.

Raccontata da

mercoledì 1 aprile 2026·cnbc.com
FDA approves Eli Lilly's GLP-1 pill, opening the next phase of the weight loss drug market
The FDA approval of Eli Lilly's GLP-1 pill Foundayo comes nearly three months after Novo Nordisk's oral version of Wegovy hit the market.
mercoledì 1 aprile 2026·ft.com
Eli Lilly wins US approval for weight-loss drug in pill form
New drug Foundayo sets up battle with Novo Nordisk for oral obesity drugs

mercoledì 1 aprile 2026·

upi.com

FDA approves Eli Lilly's GLP-1 weight-loss pill Foundayo - UPI.com

The Food and Drug Administration on Wednesday approved Eli Lilly's pill version of a GLP-1 medication for weight loss.

mercoledì 1 aprile 2026·

usatoday.com

Eli Lilly wins approval for new weight-loss pill. What to know.

Eli Lilly's new weight-loss pill, sold under the name Foundayo, gives consumers a second option for a non-injectable GLP-1.

mercoledì 1 aprile 2026·

wired.com

FDA Approves Eli Lilly’s GLP-1 Pill

Eli Lilly’s once-daily Foundayo is the second obesity pill to receive FDA approval. It will compete with Novo Nordisk’s pill version of Wegovy.

giovedì 2 aprile 2026·

cnbc.com

Novo Nordisk says Wegovy pill outperforms Lilly’s oral GLP-1 in cross-trial comparison

Novo and Eli Lilly are both trying to shape the narrative of their rival pills, considered to be the start of the next phase of the weight-loss drug era.